Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review

Abstract

Aim : To gather and review data describing the epidemiology of schizophrenia and clinical guidelines for schizophrenia therapy in seven Central and Eastern European countries, with a focus on negative symptoms. Methods : A literature search was conducted which included publications from 1995 to 2012 that were indexed in key databases. Results : Reports of mean annual incidence of schizophrenia varied greatly, from 0.04 to 0.58 per 1,000 population. Lifetime prevalence varied from 0.4% to 1.4%. One study reported that at least one negative symptom was present in 57.6% of patients with schizophrenia and in 50–90% of individuals experiencing their first episode of schizophrenia. Primary negative symptoms were observed in 10–30% of patients. Mortality in patients with schizophrenia was greater than in the general population, with a standardized mortality ratio of 2.58–4.30. Reasons for higher risk of mortality in the schizophrenia population included increased suicide risk, effect of schizophrenia on lifestyle and environment, and presence of comorbidities. Clinical guidelines overall supported the use of second-generation antipsychotics in managing negative symptoms of schizophrenia, although improved therapeutic approaches are needed. Conclusion : Schizophrenia is one of the most common mental illnesses and poses a considerable burden on patients and healthcare resources alike. Negative symptoms are present in many patients and there is an unmet need to improve treatment offerings for negative symptoms beyond the use of second-generation antipsychotics and overall patient outcomes.

Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future

“…The introduction of antipsychotics was a major breakthrough in the field of psychiatry, leading to their inclusion in a number of guidelines as well as Essential Medicine Lists (EML) across countries to enhance rational prescribing (9,(14)(15)(16)(17)(18)(19). However, despite the plethora of guidelines, in clinical practice prescribing can differ appreciably from the suggestions (20)(21)(22)(23).…”

Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits

“…In contrast to delusions and hallucinations that constitute the positive symptoms of schizophrenia, negative symptoms characterize absent or diminished behavior and include motivational deficits, social withdrawal, poverty of speech, decreased emotional reactivity and psychomotor expression, and deficits in volition (10,11). Negative symptoms are common and are thought to be present in over half of patients, with reports in the literature ranging from 60 to 90% (12,13). These negative symptoms may be primary in nature (i.e., thought to be driven by underlying pathophysiology of the disorder).…”

Forecasting Schizophrenia Incidence Frequencies Using Time Series Approach

“…1 Generally, epidemiologic research has built a powerful knowledge base over the past quarter hundred years, and this knowledge foundation will continue to make contributions to public well-being efforts at prevention of schizophrenia in the coming decades. 19 We used HWES method to model and forecast the schizophrenia incidence frequencies using the data from 91 months from 2008 to 2016. Lots of studies have used the HWES method with both additive and multiplicative approaches to analyze time series data in medical areas.…”